SCHEMBL5723833

SCHEMBL5723833

CCOC(=O)c1coc(N2CC(C(C)(C)C)C2O[SiH](c2ccccc2)c2ccccc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
GABRA2 P47869 3/20 0.35
GABRB2 P47870 3/20 0.35
ALDH1A1 P00352 5/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 2/20 0.33
NLRP3 Q96P20 1/20 0.33
LMNA P02545 2/20 0.33
RIPK1 Q13546 1/20 0.33
CASP3 P42574 1/20 0.32
CASP7 P55210 1/20 0.32
CASP8 Q14790 1/20 0.32
HPGD P15428 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724044 0.89 DAGLA (0.35) HCRTR1HCRTR2CYP1A2ALDH1A1KDM4E
SCHEMBL5724986 0.88 HCRTR1 (0.35) HCRTR1HCRTR2
SCHEMBL5723739 0.86 ALDH1A1 (0.38) HCRTR1HCRTR2ALDH1A1
SCHEMBL6836540 0.85 TBXA2R (0.35) HCRTR1HCRTR2RIPK1
SCHEMBL5724371 0.83 HCRTR1 (0.36) HCRTR1HCRTR2ALDH1A1MEN1KMT2A
SCHEMBL5724350 0.82 HTR2C (0.36) HCRTR1HCRTR2CYP1A2ALDH1A1GAA
SCHEMBL5724359 0.81 HCRTR1 (0.33) HCRTR1HCRTR2RIPK1
SCHEMBL5724184 0.81 RIPK1 (0.39) HCRTR1HCRTR2RIPK1ADORA2B
SCHEMBL5723868 0.81 NPC1 (0.41) CYP1A2MAPTALDH1A1L3MBTL1MEN1
SCHEMBL5724097 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD HCRTR1 4497/4885HCRTR2 4805/4885CYP1A2 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.